MT-001 anti-PACAP monoclonal antibody Updated Jul 2
MT-001 is too early for a binary trade, no human data exists yet and Phase 2a data is two+ years out. The real near-term story for INM is the reverse-merger close (expected by Dec 31, 2026) and whether the $290M PIPE fully funds through 2028 as promised. Post-merger the ticker changes, so current INM holders are effectively buying Mentari's preclinical pipeline at the merged entity's valuation. Watch for the IND/CTA filing mid-2026 as a first proof of life.
- PACAP is a newly validated migraine target, Lundbeck's bocunebart (also anti-PACAP) succeeded in a Phase 2b study, de-risking the mechanism (source: fiercebiotech.com)
- The $290M oversubscribed PIPE (led by Fairmount, with a16z, Janus Henderson, Commodore Capital) funds operations through 2028, unusual depth for a preclinical asset (source: biospace.com)
- Designed for convenient subcutaneous dosing with best-in-class claims based on in vitro potency vs. benchmarks (source: inmedpharma.com press release)
- No human data exists, MT-001 is still preclinical and has not filed an IND. Phase 2a data is not expected until 2028, years away from any pivotal catalyst (source: benzinga.com)
- Earlier anti-PACAP programs failed: Amgen's AMG 301 (PAC1 receptor antagonist) and Eli Lilly's LY3451838 both flopped in Phase 2 (source: p05.org)
- Intense competition, Lundbeck's bocunebart is already in Phase 2b with positive data; Slate Medicines launched with $130M; Vedana debuted with $46M; all targeting PACAP (source: fiercebiotech.com, biopharmadive.com)